From Regional to Global: how Pfizer reworked the pharmaceutical business model

16 March 2010

Jorge Puente, Regional President of WW Pfizer gives MeetTheBoss.tv an inside look into how Pfizer became global.

Mr Puente explained to Adam Burns, editor in chief of meettheboss.tv, that the fact he did not know there was a Pfizer international office until the firm invited him to do a lecture, really became a telltale sign that change needed to take place at the pharmaceutical giant.

He goes on to develop the example by supplying the underlying corporate culture that led Pfizer International to generate more revenues then Pfizer US. The ability to 'have this customer oriented philosophy where we are there for the customer first' was the basis for change.

When Pfizer looks globally at providing medication the need to look at the needs of patients in regions becomes a much greater challenge then looking at providing a blanket of solutions. Mr Puente cites the example of diabetes in the USA, as opposed to Asia, to show why going global needed to be though about differently.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical